Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) shares were up 2.8% during mid-day trading on Monday . The stock traded as high as $121.88 and last traded at $121.42, with a volume of 262,693 shares traded. The stock had previously closed at $118.12.
Several research analysts have recently issued reports on JAZZ shares. Zacks Investment Research cut Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, July 20th. Barclays PLC reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 10th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $188.00 target price (up previously from $186.00) on shares of Jazz Pharmaceuticals PLC in a research note on Monday, June 6th. BMO Capital Markets reaffirmed an “outperform” rating and set a $195.00 target price (up previously from $193.00) on shares of Jazz Pharmaceuticals PLC in a research note on Thursday. Finally, Janney Montgomery Scott initiated coverage on Jazz Pharmaceuticals PLC in a research note on Thursday, August 25th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $185.67.
The stock has a market capitalization of $7.35 billion, a P/E ratio of 21.34 and a beta of 0.93. The firm has a 50 day moving average price of $136.48 and a 200-day moving average price of $139.48.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/jazz-pharmaceuticals-plc-jazz-trading-up-2-8.html
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.80 by $0.17. The firm earned $381 million during the quarter, compared to analyst estimates of $376.40 million. Jazz Pharmaceuticals PLC had a net margin of 25.46% and a return on equity of 28.39%. The firm’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period last year, the business posted $2.41 earnings per share. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post $10.08 earnings per share for the current fiscal year.
In other Jazz Pharmaceuticals PLC news, CMO Karen L. Smith bought 580 shares of the firm’s stock in a transaction on Wednesday, July 13th. The stock was purchased at an average cost of $143.63 per share, with a total value of $83,305.40. Following the completion of the purchase, the chief marketing officer now owns 13,574 shares in the company, valued at $1,949,633.62. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Seamus Mulligan sold 27,968 shares of the business’s stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $128.32, for a total value of $3,588,853.76. Following the completion of the transaction, the director now directly owns 1,072,411 shares of the company’s stock, valued at $137,611,779.52. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com’s FREE daily email newsletter.